Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of GR1803 versus daratumumab + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
CTR20260453Phase 3Active
- Sponsor
- Zhixiang Jintai
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of velinotamig in multiple myeloma (MM) (2 arms), sponsored by Zhixiang Jintai. Primary endpoint: Progression-free survival. Started Feb 2026; status: active.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20260453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260453.